Pesce, Carlos, Conxita Leal, Hernán Pinto, Gabriela González, Marco Maggiorini, Michael Schneider, and Peter Bärtsch. Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol. 6:158-166, 2005.-To investigate the determinants of acute mountain sickness (AMS) and of summiting in expedition-style mountaineering, 919 mountaineers (15.4% female) leaving Aconcagua Provincial Park at the end of an expedition to Mt. Aconcagua (6962 m) via the normal route were retrospectively evaluated by questionnaires. Symptoms of AMS were reported from the day when mountaineers felt worst. The prevalence of AMS, defined as a Lake Louise Score (self-assessment) Ͼ 4, was 39%. Low AMS scores were associated with faster ascent rates. The following parameters were independent predictors for AMS: no susceptibility for AMS (odds ratio, OR, 0.24; 95% confidence interval 0.17 to 0.35) more than 10 exposures per year above 3000 m (OR 0.60; 0.41 to 0.86), and previous exposures above 6000 m (OR, 0.48; 0.33 to 0.68). This last variable increased the OR for summiting 3.7-fold while female gender reduced this OR to 0.41 (0.25 to 0.67). Susceptibility and few exposures to high altitude are major predictors for AMS on Aconcagua, but AMS does not substantially reduce the chances for summiting. Those who are often in the mountains and who have already climbed to altitudes above 6000 m and are not susceptible for AMS have the best options for summiting Aconcagua.
INTRODUCTION E
PIDEMIOLOGICAL STUDIES on the prevalence of AMS in Alpine mountaineers (Maggiorini et al., 1990; Schneider et al., 2002) and in tourists in the Rocky Mountains (Honigman et al., 1993) demonstrate that the major determinants of the prevalence of AMS are the rate of ascent, individual susceptibility, and altitude of residence or altitude exposure in the preceding weeks. The type of altitude exposure involved in these studies is characterized by a continuous ascent over one to at most a few days to a final altitude, usually between 3000 and 5000 m, at which AMS was assessed.
Continuous ascent over many days to alti-tudes of 5000 to 6000 m is the typical type of exposure in Himalayan trekking. Epidemiological studies in trekkers have shown that a slow ascent rate is associated with less AMS (Hackett et al., 1976; Hackett and Rennie, 1978; Kayser, 1991) . A more recent investigation (Murdoch, 1995; Murdoch, 1999) showed, however, that the prevalence of AMS was similar (between 50% and 60% over a large range of ascent rates from 200 to 600 m per day), suggesting that the overall ascent rate might be determined by susceptibility to AMS. On expeditions to altitudes of 7000 m and higher, ascent is usually characterized by gaining altitude over a chain of camps interrupted by rest days or by descents to lower camps for acclimatization before ascending to the next higher level. The prevalence and the determinants of AMS in this setting and the impact AMS has on the chances of summiting are not known, despite the fact that expedition-style mountaineering has become very popular and is nowadays offered by commercial organizations.
To assess the prevalence of AMS and its impact on the chances of summiting, we obtained questionnaires from 919 mountaineers leaving the Aconcagua National Park at the end of their expeditions. They were all members of parties that had the goal to climb Mount Aconcagua (6962 m) via the North West Face over the normal route, which does not pose major technical difficulties and involves two or three high camps.
METHODS

Study design
All mountaineers that ascend Aconcagua over the normal route on the northwestern side use Plaza de Mulas (4250 m) as a base camp and have two or three high camps, one at 4950 m (Canada), the next at 5350 m (Nido de Condores), and the highest at 5800 m (Berlin). From Plaza de Mulas, mountaineers usually descend through Laguna de los Horcones for leaving the Aconcagua National Park. During the study period of January 3 to January 31, 2001, all mountaineers descending from Plaza de Mulas and passing by at Laguna de los Horcones were asked to fill in a questionnaire that was available in four languages (Spanish, English, French, and German) . Four to six investigators were present to help and to crosscheck the answers.
Questionnaire
The questionnaire contained five sections. Section A referred to demographic data, gender, age, nationality, weight and height, altitude of residence, tobacco and alcohol consumption before and during the expedition, medical history, current medication, and drug intake on the mountain.
Section B assessed previous exposure to altitude: average of yearly exposures to altitudes above 3000 m, lifetime maximum altitude before the current expedition, and frequency of symptoms on previous exposures, such as headache, gastrointestinal symptoms, dizziness, sleep disturbances, and peripheral edema, which were all rated with the frequency at which they had occurred: never, 0; rarely, 1; frequently, 2; and regularly, 3 (for details see Schneider et al., 2002) . History of high altitude pulmonary (HAPE) or cerebral edema (HACE) was also obtained.
Section C assessed the characteristics of the current expedition, such as weekly training time, altitude exposure (days spent above 3000 m during the two previous months and during the full year), rate of ascent (how many days it took to reach the typical altitudes for the camps at 4200, 4950, 5350, 5800, and 6250 m) and the summit (6962 m), and reasons for not reaching the summit (when appropriate).
Section D was devoted to AMS during the expedition. Subjects were asked to report the altitude and the day of the expedition on which symptoms of AMS were most severe. They were asked to quantify symptoms for this occasion by filling in a Lake Louise Score questionnaire . Intake of drugs for treatment and prevention of altitude illnesses (analgesics, acetazolamide, glucocorticoids, and nifedipine), intake of hypnotics, and the use of oxygen or hyperbaric chambers were also recorded.
Rescue by helicopter. The number of mountaineers rescued by helicopter, cause, location and altitude were obtained from the helicopter companies involved in rescue on Aconcagua. No questionnaires could be obtained from these mountaineers.
Definition of AMS and of susceptibility to AMS
AMS was defined by a self-reported LLS Ͼ 4, since it was shown in a mountaineering population that this score has sensitivity and specificity comparable to the AMS-C score of the environmental symptom questionnaire (Sampson et al., 1983) for identifying individuals who have a degree of AMS associated with feeling sick and reduced activity, thus identifying mountaineers that have a clinically relevant degree of AMS Maggiorini et al., 1998) . Susceptibility to AMS was based on the history of symptoms of AMS that had occurred on previous exposures, which were assessed by section B of the questionnaire. Also, 99.4% of the mountaineers reported to have been at least once per year above 3000 m. Instead of defining susceptibility, we preferred to define nonsusceptibility, as explained elsewhere (Schneider et al., 2002) . Mountaineers were considered not susceptible when they reported to suffer rarely or never from headache and their total history score was Ͻ4.
Statistical methods
Data were analyzed by the statistic software SAS 8.02. For the analysis of frequencies, we used a chi-squared test, the Fisher exact test, and the Cochran-Armitage Trend Test. Bivariate continuous scaled data were analyzed by t test. For multivariate analysis, we used logistic regression (Proc logistic SAS software).
Exclusions. Only subjects with complete datasets were included in the multivariate statistical analyses. Furthermore, we excluded 80 mountaineers who declared that the summit was not their objective.
RESULTS
Of the 1403 mountaineers who had entered the Aconcagua Park from middle of December to middle of January (i.e., the number corresponding to those that were expected to leave the park during the study period) 919 (ϭ 66%) agreed to participate in this investigation. During the study period, 33 mountaineers were evacuated from the northwest side of the mountain by helicopter because of illness (21 cases of HAPE, 6 cases of HACE, and 6 mountaineers with frostbite). There were no casualties during the study period. The prevalence of severe HACE necessitating rescue by helicopter was 0.4% (6 cases of 1403 at risk) and of severe HAPE 1.5% (21 out of 1403) in the total population at risk. The prevalence of minor forms of HACE and HAPE with recovery by descent and treatment on site is not known. The overall prevalence of AMS in the population examined was 39% (Table 1) . Table 1 shows the characteristics of the mountaineering population on the North West Face of Aconcagua. Data that need to be pointed out are the low percentage of female mountaineers and the relatively fast mean ascent rate of 611 m/day. Almost half of the mountaineers took medication at least once, mostly for symptomatic treatment (analgesics), and 18% took medication that is recommended for prevention or treatment of AMS (acetazolamide or glucocorticosteroids). Since 9% of the mountaineers did not intend to climb the mountain, the success rate on Aconcagua via the northwest route is 542 out of 839 (65%). Almost half of the mountaineers have considerable experience in mountaineering; they spend more than 10 days per year above 3000 m and have previously been at altitudes above 5000 m.
Figures 1 and 2 demonstrate that more frequent altitude exposure and greater maximum previous height are significantly associated with a lower AMS prevalence and a higher rate of summiting. Table 2 presents the adjusted odds ratios (OR) for the prevalence of AMS and chances for summiting. This multivariate analysis with dichotomized data shows that gender, age, body mass index, training hours at low altitude, smoking, and mountaineering activity in the preceding 2 months were not significantly associated with AMS and summiting. Not being susceptible to AMS, previous maximum altitudes above 6000 m, and more than 10 days of exposures above 3000 m/y are associated with significantly lower OR for AMS (between 0.24 and 0.60), while the OR of 0.69 (0.48 to 1.00) for the age group above 40 yr is of border-line significance. A significant decrease of the OR for summiting was found for female gender (by 59%), while the chances for summiting significantly increase by 263% in those who had previously climbed to altitudes above 6000 m and by 64% for those not susceptible to AMS.
Susceptibility to AMS is significantly associated with an increased prevalence of AMS in the bivariate (Fig. 3 ) and multivariate analysis ( Table 2 ). The percentage of summiteers decreases slightly in those with a higher history score (Fig. 3 ). The multivariate analysis shows significant independent effect of susceptibility to AMS on the odds ratio for summiting (Table 2) .
Interestingly, the ascent rate has little influence on the prevalence of AMS. The Spearman rank correlation between AMS score and ascent rate yields a slightly negative correlation with a coefficient of Ϫ0.15 (p Ͻ 0.01), because those with a very low score ascended faster, whereas average ascent rate was almost identical between Lake Louse Scores between 2 and 6. Table 3 shows a comparison of mountaineers with slower and faster ascent, using an average altitude gain of 600 m/day as the cutoff value. Those ascending faster are less susceptible to AMS, have more mountaineering experience, have less AMS, and take fewer drugs on the mountain. There is, however, no significant difference in the percentage of summiteers between the faster and slower group. 
DISCUSSION
This study shows that AMS has no significant influence on the chances of reaching the summit. Our data also indicate that those who are often in the mountains and who have already climbed to altitudes above 6000 m have the best options for summiting Aconcagua. Furthermore, a faster ascent rate is associated with a lower rather than a higher prevalence of AMS in expedition-style climbing to an altitude of about 7000 m, in contrast to rapid ascents within 1 to 2 days in the Rocky Mountains or Alps, where those with greater ascent rates get more AMS.
Acute Mountain Sickness
The overall prevalence of AMS in this study is 39%, with an overall ascent rate of 612 m/day. These data are in agreement with the overall prevalence of 29% found in Alpine mountaineers (ascent rate 800 m/day) at an altitude of 4559 m in a study using a comparable definition of AMS (Schneider et al., 2002) . The 50% prevalence of AMS at altitudes between 4200 and 5500 m reported in trekkers ascending 350 to 400 m/day used a definition of AMS based on a much lower cutoff and is therefore not comparable with the reported data Gertsch et al., 2004; Hackett et al., 1976) . Our estimation of the true incidence of AMS may be biased by the fact that about one-third of the mountaineers at risk did not participate in the study. Furthermore, we assessed AMS retrospectively at only one time during the whole exposure: at the time when people felt worst. We are confident that subjects remember the symptoms they had on the day when they felt worst quite well at the end of an expedition lasting 2 to 3 weeks. We also assume that the severity of AMS on the worst day reflects the overall impairment by AMS during the expedition. Comparison with data obtained on the prevalence of AMS in a large epidemiological study in Alpine mountaineers and Himalayan trekkers suggests that our approach is reasonable, and our data fit well with the concept of higher prevalence of AMS with increasing altitude.
At first sight, the finding that ascent rates are constant over a large range of AMS scores (Fig. 4) is surprising. It contrasts with studies in Alpine mountaineers in whom fast ascent is a major predictor of AMS (Schneider et al., 2002) . This apparently paradoxical finding might be explained by the setting of the expedition-style mountaineering. Mountaineers are told to take a day of rest when symptoms of AMS occur and to descend to lower camps for recovery when symptoms do not resolve despite a day of rest. Therefore, those with less or no symptoms of AMS can ascend faster, while those with AMS ascend more slowly. Others might ascend more slowly from the beginning because they know about their susceptibility or they follow general guidelines about ascent rates (Basnyat and Lancet 2003; Hackett & Roach, 2001 ).
Our observations demonstrate that AMS during the expedition is not necessarily associated with not reaching the summit. Comparison of mountaineers with low and fast ascent rates (Table 3) suggests that those with more symptoms of AMS merely ascend slower and use more drugs on their way to the summit. This observation is in accordance with the results of a study by Murdoch (1995) , who reported a similar prevalence of AMS in Himalayan trekkers over a large range of ascent rates from 200 to 600 m per day, suggesting that the overall ascent rate might be determined by susceptibility to AMS.
A history of AMS on previous exposures was the most important independent predictor of AMS. Those not susceptible had a 76% lower risk for developing AMS with a narrow 95% confidence interval of 65% to 83%. This finding is not surprising and is in accordance with previous studies (Forster, 1984; Honigman et al., 1993; Richalet et al., 1988; Schneider et al., 2002) . More than 10 days of high altitude exposures above 3000 m per year and a previous maximum altitude above 6000 m were also associated with a lower AMS prevalence. Since there was no significant effect for altitude exposure Ͼ3000 m in the 2 months prior to the expedition, we can exclude better preacclimatization as the explanation of lower AMS prevalence in those who climbed more often and go higher. This finding may reflect self-selection and more experience in how to deal with minor symptoms of AMS or how to avoid more severe AMS most efficiently. Although the variables susceptibility, time spent in the mountains, and maximal altitude reached were independent predictors for the chances of reaching the summit, it is likely that expedition mountaineering leads to the selection of people who are less susceptible to AMS and have good physical performance at high altitude.
Summiting
Although not being susceptible to AMS increases the odds ratio for summiting by 64% (1.23 to 2.38, 95% confidential interval), the occurrence of AMS during the ascent does not influence the odds to summit Aconcagua (Table  2) . Thus, our data demonstrate that AMS does not prevent mountaineers from getting to the summit. It merely slows them down and increases the use of drugs for treatment and prevention, as shown in Table 3 .
The most important independent predictor for summiting is previous exposures to altitudes above 6000 m ( Fig. 2 and Table 2 ). Bivariate analysis indicates that summiters spent more time at altitude throughout the year, presumably climbing (Fig. 1) . This strong influence of previous experience regarding climbing and maximum altitude may to some extent reflect a self-selection of individuals particularly capable of climbing high peaks. Nevertheless, it seems reasonable to tell those who want to improve their chances on the high mountains to prepare themselves by going mountaineering often, starting at lower altitudes first and working their way up over the years.
In addition, male gender independently increased the chances of reaching the summit of Aconcagua in this study. While we have no explanation for the gender effect, we suggest that the lower OR for summiting of those older than 40 yr could be related to the age-associated decrease of V O 2max , which can amount to about 1% per year above 30 yr (Wilson and Tanaka, 2000) , and it may point to the importance of having good aerobic capacity on very high mountains, as has been demonstrated in Himalayan climbers (Richalet et al., 1988) .
Further observations
There were no casualties during the study period. Four of a total number of 2670 mountaineers who ascended on the normal route via the North West Face of Aconcagua in the summer season 2000/2001 had died: one of HAPE, two of HACE, and one of trauma. Forty-five and 12 mountaineers were rescued by helicopter or mule from this side of the mountain because of HAPE and HACE, respectively. Thus, the mortality of high altitude illnesses on the normal route on Aconcagua is 0.1%, and the prevalence of severe HAPE is 1.7% and of severe HACE, 0.5%. These numbers are low compared with the mortality rate of 2.2% calculated for all British expeditions to 8000 m peaks (Pollard and Clarke, 1988) and for HAPE (about 2%, but also less severe cases included) during trekking to Everest base camp (5400 m) (Hackett et al., 1976) . Recent reviews on AMS mention the historical recommendation of an average altitude gain of 300 m/day with a rest day every fourth day for safe ascent (Basnyat and Murdoch, 2003; Hackett and Roach, 2001) . Although these authors suspect that their advice is too conservative, evidence for this assumption has been lacking so far. The overall ascent rate in this study was about 600 m/day. Considering that only 18% of the mountaineers had taken drugs for prevention of AMS, the ascent rate observed on Aconcagua suggests that the 300-m rule is too conservative for a general recommendation and that the average mountaineer can tolerate considerably faster ascent rates, at least up to an altitude of 7000 m, without taking an irresponsible risk, as demonstrated by the low prevalence of life-threatening or lethal high altitude illnesses on Aconcagua.
The high success rate of 65% and the low prevalence of severe or lethal high altitude illnesses and trauma demonstrate that Aconcagua, a peak of almost 7000 m altitude, is fairly easy to climb via its normal route on the North West Face. Our analysis suggests that mountaineers who intend to climb it should be advised to get sufficient climbing experience on lower mountains first, and those who are susceptible to AMS should not be discouraged, but told that they need more time to get to the top.
